Enzalutamide (Xtandi) and abiraterone (Zytiga) may have similar effectiveness in metastatic castration-sensitive prostate cancer
1. The use of enzalutamide (Xtandi) and abiraterone (Zytiga) in metastatic castration-sensitive prostate cancer (mCSPC) was associated with similar overall ...







![Triple-combo chemotherapy improves survival for metastatic colon cancer [TRIBE study]](https://www.2minutemedicine.com/wp-content/uploads/2014/10/640px-Cyclophosphamide_iv-350x250.jpg)

